688520 Stock Overview
A biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sinocelltech Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥36.93 |
| 52 Week High | CN¥61.00 |
| 52 Week Low | CN¥34.34 |
| Beta | 0.52 |
| 11 Month Change | -6.15% |
| 3 Month Change | -25.90% |
| 1 Year Change | -35.66% |
| 33 Year Change | -46.69% |
| 5 Year Change | n/a |
| Change since IPO | -49.46% |
Recent News & Updates
Shareholder Returns
| 688520 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -7.9% | -5.8% | -2.8% |
| 1Y | -35.7% | -29.1% | -21.0% |
Return vs Industry: 688520 underperformed the CN Biotechs industry which returned -29.1% over the past year.
Return vs Market: 688520 underperformed the CN Market which returned -21% over the past year.
Price Volatility
| 688520 volatility | |
|---|---|
| 688520 Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 688520's share price has been volatile over the past 3 months.
Volatility Over Time: 688520's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,313 | Liangzhi Xie | www.sinocelltech.com |
Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2.
Sinocelltech Group Limited Fundamentals Summary
| 688520 fundamental statistics | |
|---|---|
| Market cap | CN¥16.46b |
| Earnings (TTM) | -CN¥168.81m |
| Revenue (TTM) | CN¥2.17b |
7.6x
P/S Ratio-97.4x
P/E RatioIs 688520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688520 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.17b |
| Cost of Revenue | CN¥117.33m |
| Gross Profit | CN¥2.05b |
| Other Expenses | CN¥2.22b |
| Earnings | -CN¥168.81m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 94.60% |
| Net Profit Margin | -7.78% |
| Debt/Equity Ratio | -518.5% |
How did 688520 perform over the long term?
See historical performance and comparison